
https://www.science.org/content/blog-post/scorched-earth-policy-wyeth-s-princeton-site
# A Scorched-Earth Policy at Wyeth's Princeton Site? (January 2010)

## 1. SUMMARY
The article describes a secondhand report about the shutdown of Wyeth's Princeton research site. The author expresses concern that instead of following typical industry practice of donating surplus equipment and glassware to academic labs, the site appears to be destroying everything—breaking glassware, discarding equipment, and sending chemical reagents to a waste disposal firm for incineration.

The author questions whether this "scorched-earth" approach is actually happening, noting that while disposing of commercial reagents sometimes isn't worth the paperwork, equipment and glassware should definitely be salvaged rather than wasted. The post seeks additional details and confirmation from readers about whether everything is really being thrown into dumpsters.

## 2. HISTORY
The Wyeth Princeton site closure occurred during a major transformation in the pharmaceutical industry. In October 2009, Pfizer completed its $68 billion acquisition of Wyeth, leading to significant consolidation and site rationalization. The Princeton facility was one of several research sites affected by the merger integration.

This closure reflected broader industry trends in the late 2000s-early 2010s. Major pharmaceutical companies were restructuring their R&D operations, moving away from large centralized research campuses toward more flexible models. The period saw numerous site closures across the industry, including facilities from Merck, AstraZeneca, and Novartis.

The disposal methods described in the article—while appearing wasteful—were not uncommon during large-scale pharmaceutical site closures. Safety regulations, liability concerns, and the cost of proper decontamination and documentation often made equipment donation impractical, especially for facilities that had handled diverse chemical and biological materials over decades.

The Princeton area's biopharma research landscape continued to evolve, with some former pharma scientists transitioning to smaller biotech companies or academic positions in the region. The broader industry shift toward outsourcing and more targeted research approaches accelerated in subsequent years.

## 3. PREDICTIONS
The article did not contain explicit predictions about future developments. It was focused on documenting and seeking information about a current situation rather than forecasting future trends or outcomes.


## 4. INTEREST
Rating: **2/10**
This article documents a specific incident during pharmaceutical industry consolidation but lacks broader analytical depth and represents a narrow slice of industry practice rather than substantive scientific or policy developments.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20100128-scorched-earth-policy-wyeth-s-princeton-site.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_